SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments
News
Alzecure enters collaboration and with Lilly for Alzheimer’s project
Partnership grants Lilly global rights to Alzstatin ACD680
Survodutide trial data show targeted visceral and liver fat reductions
Phase 3 results highlight metabolic benefits alongside weight loss
Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
Late‑breaking EULAR results highlight sustained responses through week 52
European approval enables measles protection with CSL’s immunoglobulin Privigen
Commission authorisation expands access to passive measles prophylaxis for vulnerable patients
JJP Biologics reports positive interim phase 1b data for nebaprubart
Early clinical activity supports expansion into broader IgA‑mediated conditions
Immunotherapy boost can spare more bladder cancer patients major surgery
Adding durvalumab to chemoradiation helps people avoid having their bladder removed
Deep Science Ventures and MDC partner to accelerate brain treatments
New collaboration aims to break barriers in brain‑targeted drug discovery
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer
Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen
Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer
Resolution Therapeutics hails positive 4‑year MATCH data in liver cirrhosis
Findings strengthen rationale for EMERALD trial of engineered macrophage therapy RTX001
KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
Phase 1 study to assess safety and early efficacy of KMA‑targeting car‑t in multiple myeloma
Pepaxti study supports use in wider myeloma population
Phase 2 bridge data show consistent outcomes in patients with impaired kidney function
UCB reports positive outcomes for bimekizumab in psoriatic arthritis
Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic
AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension
Baxdrostat delivers clinically meaningful blood pressure reductions in phase 3 BaxHTN trial
